<DOC>
	<DOC>NCT03022461</DOC>
	<brief_summary>The purpose of this clinical investigation is to report the long term survival and incidence of adverse events in the patients who were implanted with HM3 in the CE Mark Study and continue to be ongoing with the HeartMate 3 LVAS after the CE Mark Study 2 year follow-up. The study will be a single arm, prospective, multi-center, non-blinded and non-randomized study, intended to report on the long term use of the HeartMate 3 LVAS in those patients that completed the 2-year follow-up in the HeartMate 3 CE Mark study.</brief_summary>
	<brief_title>HeartMate 3 CE Mark Study Long Term Follow-up</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1. Patient or legal representative has signed Informed Consent Form (ICF). 2. Patient was enrolled in the HeartMate 3 CE Mark Study and continues to be supported with the HeartMate 3 LVAS after the 2 year CE Mark study followup. 1. Patient does not consent to the continued data collection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>Cardiomyopathies</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Heart-assist Devices</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>